Investors

/Investors
Investors 2019-01-03T10:17:20+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.95
0.06 (2.08%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :32,675
Date :05-24-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801

May 21st, 2019|Comments Off on Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801

NEW YORK, May 21, 2019 /PRNewswire/ -- ORMD-0801 reaches significant milestone on path to potentially be the first commercial oral insulin capsule for the treatment of Type 2 diabetes Close to 300 patients have now [...]

Oramed to Present at ThinkEquity Conference

April 29th, 2019|Comments Off on Oramed to Present at ThinkEquity Conference

NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming [...]

Oramed to Present at 3rd Annual Clinical Trials Summit

April 11th, 2019|Comments Off on Oramed to Present at 3rd Annual Clinical Trials Summit

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the [...]

Oramed Patent Allowed in the U.S. for Oral Exenatide

April 4th, 2019|Comments Off on Oramed Patent Allowed in the U.S. for Oral Exenatide

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the [...]